Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive‐Stage Small Cell Lung Cancer

BACKGROUND: Small cell lung cancer (SCLC) represents approximately 15% of lung cancers, and approximately 70% are diagnosed as extensive‐stage SCLC (ES‐SCLC). Although ES‐SCLC is highly responsive to chemotherapy, patients typically progress rapidly, and there is an urgent need for new therapies. Im...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Melosky, Barbara, Cheema, Parneet K., Brade, Anthony, McLeod, Deanna, Liu, Geoffrey, Price, Paul Wheatley, Jao, Kevin, Schellenberg, Devin D., Juergens, Rosalyn, Leighl, Natasha, Chu, Quincy
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Lung Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648366/
https://ncbi.nlm.nih.gov/pubmed/32860288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0193
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares